laser
DeviceOther names: IncontiLaseTM, IncontiLase
NCT Number: NCT03296241
Stress urinary incontinence (SUI) is a common complaint in women after childbirth. The aim of this study was to evaluate the efficacy and safety of non-ablative Er:YAG laser therapy in the treatment of SUI and improvement of sexual gratification in parous women. 114 premenopausal parous women with SUI were randomized in two groups of 57 women; a laser intervention group and sham control (placebo) group. Both groups were treated according to the IncontiLaseTM clinical treatment protocol for SUI with non-ablative thermal-only Er:YAG laser, except that there was no energy output when treating the sham group. Patients were blinded to the allocation. At baseline and 3 months after treatment patients were clinically examined, answered questionnaires for SUI severity sexual function assessment and their pelvic floor muscle (PFM) function was assessed with perineometry. The improvement in the laser group will be compared to the improvement in the sham group.
Looking for future studies?
Notify Me35 year–65 year
Female
Interventional
Not applicable
Stress urinary incontinence (SUI) is a common complaint in women after childbirth. It affects their quality of life and sexual satisfaction and is one of the major reasons for gynaecological surgery. There is a need for effective non-invasive treatment alternatives. The aim of this study was to evaluate the efficacy and safety of non-ablative Er:YAG laser therapy in the treatment of SUI and improvement of sexual gratification in parous women. 114 premenopausal parous women with SUI were randomized in two groups of 57 women; a laser intervention group and sham control (placebo) group. Both groups were treated according to the IncontiLaseTM clinical treatment protocol for SUI with non-ablative thermal-only Er:YAG laser, except that there was no energy output when treating the sham group. Patients were blinded to the allocation. At baseline and 3 months after treatment patients were clinically examined, answered questionnaires for SUI severity sexual function assessment and their pelvic floor muscle (PFM) function was assessed with perineometry. Validated International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form (ICIQ-UI SF) was used as the primary outcome measure. The Pelvic Organ Prolapse Urinary Incontinence Sexual Questionnaire short form (PISQ-12) and The Female Sexual Function Index (FSFI) were used to assess the sexual function. Patients were monitored for discomfort and side-effects during treatment and follow up period.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: IncontiLaseTM, IncontiLase
Other names: placebo
Time frame: at 3 months after intervention
International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form
Time frame: at 3 months after intervention
The Pelvic Organ Prolapse Urinary Incontinence Sexual Questionnaire
Time frame: at 3 months after intervention
The Female Sexual Function Index, a validated generalized questionnaire utilized to assess sexual function in women in a general population.
Time frame: at 3 months after intervention
Measured with Myomed 632 perineometer with the women in supine position.
Time frame: at 3 months after intervention
Measured with Myomed 632 perineometer with the women in supine position.
Time frame: at 3 months after intervention
Measured with Myomed 632 perineometer with the women in supine position.
Time frame: up to 3 months after intervention
Monitoring for side effects during and after intervention
Dr Adolf Lukanovič
Other
Non-ablative Er:Yttrium Aluminum Garnet (Er:YAG) Laser Therapy Effect on Stress Urinary Incontinence (SUI) Related Quality of Life and Sexual Function: a Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05732844
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Barcelona, Spain
View Trial DetailsNCT03900143
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Hamburg, Germany
View Trial DetailsNCT02617472
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Phoenix, Arizona, United States
View Trial DetailsNCT07668128
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
New Taipei City, Banqiao Dist, Taiwan
View Trial Details